Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2025-06-18 00:00:00 ET · period of report 2025-06-16 · accession 0001415889-25-017691 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-18 | 2025-06-16 | KNSA | Tessari Eben | COO | S - Sale+OE | $28.28 | -17.3K | 61.6K | -22% | -$489.2K |
| D | 2025-06-18 | 2025-06-16 | KNSA | Tessari Eben | COO | M - OptEx | $8.83 | +6,500 | 78.9K | +9% | +$57.4K |
| D | 2025-06-18 | 2025-06-16 | KNSA | Tessari Eben | COO | M - OptEx | $0.00 | -6,500 | 38.5K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2025-06-16 | S | D | 17,300 | $28.28 | 61,563 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.795 and $28.645. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 2 | Common | Class A Ordinary Share | 2025-06-16 | M | A | 6,500 | $8.83 | 78,863 | D | — | — | |
| 3 | Derivative | Share Option | 2025-06-16 | M | D | 6,500 | $0.00 | 38,500 | D | $8.83 · — to 2029-09-16 | 6,500 Class A Ordinary Share | (F3) The option is fully vested and exercisable. |